MedTrace Logo

The Role of FGF23 and Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease

NCT01317186 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2011-03-17

No results posted yet for this study

Summary

In chronic kidney disease calcium (Ca) and phosphate (P) metabolism disorders are very common and also they are one of the leading causes of morbidity in these population. FGF23 is a novel factor that contributes Ca-P disorders. It has been hypothesized that FGF 23 increase is mediated by asymmetric dimethylarginine (ADMA). The aim of the study is to evaluate this hypothesis.

Conditions

Sponsors & Collaborators

  • Ankara Education and Research Hospital

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01317186 on ClinicalTrials.gov